Biotech: Page 4

  • robot hand pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The year’s biggest biotech haul shows investors are still chasing the AI dream

    Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.

    By • April 4, 2025
  • HHS staff cuts
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip
    Opinion

    Industry leaders react to HHS being ‘reduced to a shell’

    What healthcare watchdogs have said about the far-reaching job cuts this week.

    By Meagan Parrish and Amy Baxter • April 3, 2025
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Mikael Dolsten, former CSO, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip
    Profile

    Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’

    Dr. Mikael Dolsten, Pfizer’s former chief scientific officer, is embarking on a journey of curiosity and interconnectedness in his post-Big Pharma career.

    By • April 1, 2025
  • megaphone quieted
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    With government health info in limbo, drugmakers lose credible sources

    The lack of clear communication from the government could spark wide-ranging issues in pharma — from sowing confusion about clinical trial design to further eroding public trust.

    By Alexandra Pecci • April 1, 2025
  • A 3D illustration of a DNA double helix
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A recent gene therapy death shines a light on AAV safety

    This technology brings both benefits and drawbacks for the field, which is also testing alternatives.

    By Kelly Bilodeau • March 31, 2025
  • 3D Illustration Concept of Human Respiratory System Lungs Anatomy
    Image attribution tooltip
    magicmine, iStock / Getty Images Plus via Getty Images
    Image attribution tooltip

    How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

    After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

    By • March 27, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/PharmaVoice
    Image attribution tooltip

    Biogen plots new global headquarters in Kendall Square

    The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

    By Jacob Bell • March 25, 2025
  • biotech stealth
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotechs emerging from stealth take aim at pharma’s prime targets

    The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.

    By Kelly Bilodeau • March 24, 2025
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades

    The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.

    By • March 20, 2025
  • china biotech
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The key factors shaping China’s biopharma boom

    Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.

    By Alexandra Pecci • March 19, 2025
  • Jay Hartenbach, COO, president, Diakanos Oncology
    Image attribution tooltip
    Permission granted by Diakanos
    Image attribution tooltip
    Q&A

    How non-traditional investors fuel up-and-coming biotechs when VC funding dries up

    Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.

    By • March 18, 2025
  • radioactive syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

    Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

    By Kelly Bilodeau • March 17, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip
    Q&A

    Roche’s obesity deal with Zealand Pharma tees up rival for GLP-1s

    The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

    By • March 17, 2025
  • The dome of the U.S. Capitol Building as seen at dawn.
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    IRA reforms, including a small molecule fix, could be on the table. Will Trump and the GOP make the leap?

    Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

    By • March 12, 2025
  • brain design with neuro points scattered
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep

    Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

    By • March 11, 2025
  • Biogen sign
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    What’s driving pharma’s layoffs in 2025

    Familiar foes in the industry have claimed a slew of jobs in recent months.

    By • March 10, 2025
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The time is ripe for pharma M&A. Why are drugmakers holding out?

    The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.

    By • March 6, 2025
  • Large letters spelling Amgen are seen by a wall
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    With patent losses on the horizon, Amgen refocuses its business strategy

    The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”

    By Alexandra Pecci • March 5, 2025
  • Toby Ferguson, chief medical officer, Voyager Therapeutics
    Image attribution tooltip
    Permission granted by Voyager Therapeutics
    Image attribution tooltip

    New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

    Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

    By • March 4, 2025
  • Ben Taylor, CFO, Recursion Pharmaceuticals
    Image attribution tooltip
    Permission granted by Recursion
    Image attribution tooltip
    Q&A

    AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

    Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.

    By • Feb. 27, 2025
  • Cancer vaccine
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Cancer vaccines have stumbled, but the approach is gaining new steam

    The number of candidates in development has nearly doubled over the past 15 years.

    By Kelly Bilodeau • Feb. 26, 2025
  • hands pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Its CEO died. The company scrapped a promising program. Now, for their 2nd act.

    Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.

    By Alexandra Pecci • Feb. 25, 2025
  • Capitol building, DC
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide

    Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.

    By • Feb. 25, 2025
  • Travis Coy, CFO, Immunocore
    Image attribution tooltip
    Permission granted by Immunocore
    Image attribution tooltip
    Q&A // First 90 Days

    Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

    Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

    By • Feb. 20, 2025
  • crispr cardio
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    CRISPR’s cardio catch-all drives a biotech’s broad potential

    Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

    By Kelly Bilodeau • Feb. 18, 2025